Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...

AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...

For decades, dopamine has been celebrated in neuroscience as the quintessential "reward molecule"—a chemical herald of ...

LENZ Therapeutics, Inc. , today announced the launch of "Make it VIZZable", the VIZZ consumer campaign with award-winning actor, producer and publisher, Sarah Jessica Parker ("SJP") as a brand ...

Valerie Zeko emerged from 28 years of debilitating depression after participating in a groundbreaking trial at Stanford, ...

What if the biggest driver of the antidepressant “effect” isn’t the drug, but your expectation? Learn why the placebo effect ...

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an ...

Key market opportunities in the insomnia sector include leveraging the entry of Phase II and III pipeline products anticipated to significantly impact sales, exploring varied mechanisms of action, and ...

New research has discovered that a neural circuit may explain procrastination. Scientists were able to disrupt this ...

Attention-deficit-hyperactivity disorder (ADHD) includes a mix of ongoing challenges, such as having difficulty paying attention, hyperactivity, and impulsivity. In the U.S., ADHD afflicts an ...

A new discovery about how cells communicate with each other in the body's immune system has revealed deeper insights for an ...